COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes

Purpose

This is a prospective cohort study of pregnant patients at an urban academic center diagnosed with perinatal COVID-19 infection, followed up to 6 weeks postpartum.

Condition

  • Covid19

Eligibility

Eligible Ages
All ages
Eligible Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of COVID-19 in pregnancy or within 6 months post partum - Planned delivery at Thomas Jefferson University Hospital

Exclusion Criteria

  • Declines routine COVID testing on admission - In active labor/pain/otherwise unable to provide consent

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
COVID-19 Positive Patients diagnosed with COVID-19 during pregnancy or while breastfeeding
  • Other: COVID-19 exposure
    COVID-19 exposure during pregnancy
COVID-19 vaccine Patients who receive COVID-19 vaccine during pregnancy or while breastfeeding
  • Biological: COVID-19 vaccine
    Receipt of any COVID-19 vaccine
Controls Reproductive age women exposed to COVID-19 vaccine
Pregnant Control Pregnant women who delivered at TJUH, COVID negative

Recruiting Locations

More Details

NCT ID
NCT04659759
Status
Completed
Sponsor
Thomas Jefferson University

Detailed Description

This proposal aims to provide a multi-faceted approach to addressing perinatal COVID-19 infection by (1) improving our understanding of SARS-CoV-2 antibody specificity and durability over the course of pregnancy/postpartum in mother/baby dyad (2) understanding the downstream implications of maternal systemic inflammatory response with COVID-19 infection through study of fetal inflammatory response, placental pathology, and perinatal outcomes, and (3) to evaluate the interplay between socioeconomic characteristics, COVID-19, and early neonatal outcomes. (4) Evaluate antibody generation and durability in pregnant/breastfeeding women who receive any form of the COVID-19 vaccine